A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane by Helm, J R et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A comparison of factors that influence survival in dogs with
adrenal-dependent hyperadrenocorticism treated with mitotane
or trilostane
Citation for published version:
Helm, JR, McLauchlan, GJ, Boden, LA, Frowde, PE, Collings, AJ, Tebb, AJ, Elwood, CM, Herrtage, ME,
Parkin, TDH & Ramsey, IK 2011, 'A comparison of factors that influence survival in dogs with adrenal-
dependent hyperadrenocorticism treated with mitotane or trilostane' Journal of Veterinary Internal Medicine,
vol. 25, no. 2, pp. 251-60. DOI: 10.1111/j.1939-1676.2011.0696.x, 10.1111/j.1939-1676.2011.0696.x
Digital Object Identifier (DOI):
10.1111/j.1939-1676.2011.0696.x
10.1111/j.1939-1676.2011.0696.x
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Veterinary Internal Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
A Comparison of Factors that Inﬂuence Survival in Dogs
with Adrenal-Dependent Hyperadrenocortic ism Treated with
Mitotane or Tri lostane
J.R. Helm, G. Mclauchlan, L.A. Boden, P.E. Frowde, A.J. Collings, A.J. Tebb, C.M. Elwood,
M.E. Herrtage, T.D.H. Parkin, and I. K. Ramsey
Background: Trilostane is a recognized treatment for canine pituitary-dependent hyperadrenocorticism (PDH); however, its
efﬁcacy in dogs with adrenal-dependent hyperadrenocorticism (ADH) is unknown.
Objectives: To examine factors that might inﬂuence survival in the medical management of ADH, with particular emphasis
on treatment selection.
Animals: Thirty-seven animals referred to 4 centers over a period of 12 years that had been diagnosed with ADH and
treated with either trilostane (22/37), mitotane (13/37), or both (2/37).
Methods: Retrospective analysis of clinical records.
Results: There was no statistically signiﬁcant difference between the survival times of 13 dogs treated only with mitotane
when compared with 22 dogs treated only with trilostane. The median survival time for animals treated with trilostane was 353
days (95% conﬁdence interval [CI] 95–528 days), whereas it was 102 days (95% CI 43–277 days) for mitotane. Metastatic
disease was detected in 8 of 37 dogs. There was a signiﬁcantly lower probability of survival for dogs with metastatic disease
when compared with those without metastatic disease (Po .001).
Conclusions and Clinical Importance: The choice of medical treatment for ADH may not have a major effect on survival
times. However, the presence of metastatic disease considerably decreases survival time regardless of the choice of medical
treatment.
Key words: Adrenal; Cushings; Endocrine; Treatment.
Spontaneously occurring hyperadrenocorticism (HAC)may be associated with inappropriate secretion of
ACTH from the pituitary gland (pituitary-dependent
hyperadrenocorticism [PDH]) or a primary adrenal disor-
der (adrenal-dependent hyperadrenocorticism [ADH]).
ADH is responsible for approximately 15% of all cases
of HAC and may be because of an adrenal adenoma or
carcinoma.1
Mitotane (op DDD) is a DDT derivative with cyto-
toxic effects on the adrenal cortex (zona reticularis and
zona fasciculata) and was the most common treatment
for PDH in Europe and the United States.2 Trilostane
(4,5-epoxy-17-hydroxy-3-oxoandrostan-2-carbonitrile)
is a synthetic nonhormonal steroid and a competitive
inhibitor of 3-b-hydroxysteroiddehydrogenase.3 There-
fore, mitotane is considered an adrenocorticolytic
drug, whereas trilostane is adrenocorticostatic. The clin-
ical use of trilostane in canine PDH has been reported by
several groups,4–9 and these studies have been reviewed
elsewhere.10
The reported median survival times for dogs with
PDH treated with trilostane range from 662 to 900 days
and 708 to 720 days for those treated with mitotane.11,12
There was only a signiﬁcant difference between survival
times in relation to treatment in the 2nd study,12 al-
though treatment protocols varied between the 2 reports.
Mitotane also has been the mainstay of medical treat-
ment for ADH. The reported median survival time with
this treatment is approximately 320 days.13 Only 1 small
series and 2 case reports have been published on the use
of trilostane in canine ADH.14–16 The 1st case survived
more than 560 days14 and the 2nd case survived for 117
days.16 A series of 3 dogs with adrenal tumors and met-
astatic disease survived for 295, 342, and 506 days.15
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There have been no large studies that have reported
the median survival times of dogs with ADH treated with
trilostane and compared these dogs with a similar group
of dogs treated with mitotane. Therefore, the aim of this
study was to compare factors that may be associated with
survival time after diagnosis of ADH and medical treat-
ment with mitotane or trilostane or both.
Materials and Methods
Clinical Cases
Medical records for all dogs diagnosed with ADH at each of the 4
referral-only hospitals, from January 1, 1996 to December 1, 2008,
were reviewed. The centers involved were the Small Animal Hospi-
tal of the University of Glasgow (Center 1), Davies Veterinary
Specialists (Center 2), University of Bristol Small Animal Hospital
(Center 3), and Queens Veterinary School Hospital of the Univer-
sity of Cambridge (Center 4). Only animals treated medically for
ADHwith mitotane,a trilostane,b or a combination of both and had
sufﬁcient case records available were included. Animals that had not
been treated or had been managed surgically were excluded.
Each veterinary center performed a retrospective review of med-
ical records by searching their databases for cases using the key
words ‘‘mitotane’’ and ‘‘trilostane’’ and their imaging databases
also were searched for the key words ‘‘adrenal mass,’’ ‘‘adrenal en-
largement’’ or ‘‘hyperadrenocorticism (Cushing’s).’’ The case ﬁles
were reviewed directly to distinguish between PDH and ADH.
Data obtained from the records included breed, sex, date of birth,
weight and age at diagnosis, date of diagnosis, treatment given, and
date of treatment initiation. Date of death or survival to June 1, 2008,
also was recorded.When necessary, referring veterinarians, owners, or
both were contacted. The results of pretreatment ACTH stimula-
tion tests, low-dose dexamethasone suppression tests (LDDSTs),
17-hydroxyprogesterone (17OHP) assays, urine corticoid : creatinine
ratios (UCCR), endogenous ACTH plasma concentration assays,
abdominal ultrasonography, thoracic radiography, and histopathology
(ante- or postmortem) also were recorded.
Diagnosis of HAC
Each center used similar diagnostic protocols. Suspicion of HAC
was based on history, clinical examination, and routine blood anal-
ysis. An ACTH stimulation test was performed as described
elsewhere.17 HAC was conﬁrmed if there was an exaggerated in-
crease in circulating cortisol concentration (4600 nmol/L or 21.6 g/
dL) 1 hour post-IV administration of synthetic tetracosactide.c In
animals with clinical signs and biochemical markers of HAC but
without a positive ACTH stimulation test, diagnosis was conﬁrmed
if a LDDST demonstrated inadequate suppression (440 nmol/L or
1.44mg/dL) of cortisol concentration 8 hours after IV administra-
tion of a low dose of dexamethasone.d Cortisol was measured
by external commercial laboratories by radioimmunoassays or
immunoradiometric assays validated for use in the dog, with appro-
priate quality controls.
Cases that had an inverse LDDST pattern witho50% suppression
at 3 hours18 also were included if they also had a compatible UCCR.
The test that conﬁrmed the diagnosis was recorded for later analysis.
Conﬁrmation of ADH
HAC was diagnosed as being adrenal dependent (ADH) in al-
most all cases by a combination of low endogenous ACTH
concentration (o5 ng/ml) and abdominal ultrasonography ﬁndings
(indicative of unilateral adrenal enlargement) as described previ-
ously.19 Cases also were included if they had a diagnosis of HAC
and a single large calciﬁed (410mm) adrenal gland when examined
with abdominal ultrasonography or radiography14 and responded
to trilostane or mitotane treatment. Additionally, cases that had a
diagnosis of HAC and an adrenal adenoma or carcinoma conﬁrmed
by histopathology also were included.
Blood to measure endogenous ACTH was collected as described
previously.19 Brieﬂy, blood was collected into a cooled EDTA tube on
ice, centrifuged immediately at 1,500  g for 10 minutes, and the
plasma frozen at201C. The frozen plasma was sent in a cold pack to
a single commercial laboratory, where it was analyzed by an immuno-
radiometric assaye that had been validated for use in dogs.20
All patients had abdominal ultrasonography to evaluate for
blood vessel invasion by the adrenal mass. Tumor staging was based
on the ﬁndings of abdominal ultrasonography and, when available,
thoracic radiography.
Histopathology was classiﬁed as either benign (adenoma) or ma-
lignant (carcinoma). Criteria for the classiﬁcation of a carcinoma
were histopathological evidence of invasive behavior. This included
vascular invasion, high mitotic rate (evaluated over 10 high power
ﬁelds), increased nuclear pleomorphism, a high percentage of tumor
necrosis, or some combination of these ﬁndings.
Concurrent disease at presentation as detected by clinical exam-
ination, CBCs, biochemistry proﬁles, and imaging modalities were
recorded for all cases. It was also noted if additional concurrent dis-
eases were present within 1 month of diagnosis of ADH or if the
concurrent disease developed later.
Treatment Regimen
The same treatment protocol was used for each drug at each
center.
Mitotane treatment involved an induction period followed
by a maintenance dose.13,21 During the induction period, mitotane
was administered at a dosage of 50mg/kg, up to a maximum of
1,000mg/dog, until polyphagia or polydipsia resolved and the post-
ACTH cortisol concentration was o120 nmol/L or 4.32mg/dL.21
After successful induction, a maintenance dose of mitotane was
given (initially 50mg/kg/wk). The aim was to achieve a postmedi-
cation post-ACTH stimulation test cortisol concentration of
o120 nmol/L or 4.32mg/dL.21 At the end of induction and during
the maintenance phase, a good clinical response to treatment was
deﬁned as a reduction or elimination of polyphagia and polydipsia
and return of normal coat quality with minimal adverse effects.
Mitotane maintenance doses were adjusted in amount or frequency
to achieve these aims in individual animals.
Trilostane treatment did not involve an induction period. The
starting doses of trilostane were those recommended by the manu-
facturer’s UK data sheet and were based on body weight (and
available capsule size): o5 kg: 30mg, 5.1–20 kg: 60mg, 21–40 kg:
120mg, and 440 kg: 120–240mg. All starting doses were adminis-
tered orally once daily.4 Trilostane 10mg capsules were not avail-
able during the study period.
All dogs had an ACTH stimulation test performed within 1–2
weeks of starting trilostane, a second performed between 4 and 6
weeks, and a third at 10–14 weeks. If the patient remained stable,
monitoring with ACTH stimulation tests then was undertaken every
3 months, as per the drug datasheet.
The aim of treatment was to achieve a post-ACTH stimulation
test cortisol concentration within the range 40–150 nmol/L or 1.44–
4.32mg/dL in an ACTH stimulation test performed 4 hours post-
medication5,6,9,10 with good clinical control of HAC. The initial
dose and frequency of administration were adjusted accordingly to
achieve these goals. However, dose adjustments were not necessarily
made in those dogs that had a postmedication post-ACTH stimula-
tion test cortisol concentration of 150–200nmol/L (4.32–7.2mg/dL)
but with clinical signs that had responded well to treatment.
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Excessive clinical control was deﬁned as clinical signs of hypo-
adrenocorticism and a post-ACTH cortisol concentration
o40 nmol/L. Treatment was temporarily discontinued if patients
showed clinical signs or serum electrolyte concentrations consistent
with hypoadrenocorticism. When these signs had resolved, the
dogs were started back on treatment at a lower dosage. Animals
with a post-ACTH stimulation cortisol concentration o40 nmol/L
but without clinical signs of hypocortisolism were monitored more
frequently.
Statistics
Descriptive Statistics. Population attributes treated as con-
tinuous data (age at diagnosis and weight) of the dogs in the 4
centers were assessed for normality and compared among vet-
erinary centers by a Kruskall-Wallis test (comparisons among
centers) or Mann-Whitney (Wilcoxon rank sum) test (com-
parisons between drug treatments) for nonparametric data.
Other population attributes that were treated as categorical
data (including age at diagnosis, weight, breed, reproductive
status, sex, and the presence of concurrent disease) were com-
pared by Fisher’s exact-test (differences between drug
treatments).
Survival Analysis. Survival analysis (survival in days from
date of drug treatment) was performed by a Kaplan-Meier
product limit method. Log-rank, Wilcoxon, Tarone-Ware,
and Peto-Peto Prentice tests were used to determine whether
the overall survival functions in 2 or more groups were
equal.22 Median and mean survival times for important vari-
ables were calculated. This approach was supplemented with
a Cox proportional hazards model. Potential predictor vari-
ables included method of diagnosis, drug treatment (mitotane
compared with trilostane), veterinary center (Center 1, 2, 3, or
4), breed group (Table 3), reproductive status (intact or neu-
tered), sex (female or male), age at diagnosis, weight at
diagnosis, presence or absence of blood vessel invasion, pres-
ence or absence of concurrent disease (within 1 month of
study start date), and presence or absence of metastatic dis-
ease. Reproductive status also was considered as a
polytomous categorical variable (female intact, female neu-
tered, male intact, male neutered). Age and weight were
considered as continuous, categorical, and binary variables,
based on median values (age: 11 years, 411 years; weight:
27.4 kg,427.4 kg).
Univariable Cox proportional hazards regression analyses
were performed to screen potential predictors for subsequent
inclusion in a multivariable model. Variables with a P value
.25 were considered for inclusion in the ﬁnal model-building
process. A full model containing all variables was produced.
Variables then were removed one at a time until the model
with the best ﬁt was identiﬁed. Potential for confounding be-
tween variables was assessed. Biologically plausible
interaction terms were assessed but not included in the ﬁnal
model because of the small number of observations in the
study. The proportional hazards assumption was tested for
each variable in the model by examination of Schoenﬁeld re-
siduals and graphical techniques. Further model diagnostics
were performed to identify outliers and inﬂuential points.22
All analyses were carried out by Stata 10 statistical soft-
ware.f Statistical signiﬁcance was set at P o .05 for all tests.
Power calculations were performed and it was determined
that in order to achieve 80% power to detect a hazard ratio
(HR) of 2, assuming a 5% level of signiﬁcance, 132 animals
(66 animals in each treatment group) would be required. In
contrast, to detect an HR of5, 26 animals (13 in each group)
would be adequate.
Results
Fifty-six cases were retrieved from the records. Only 37
dogs fulﬁlled all of the inclusion criteria and were in-
cluded in the study. Seven cases were excluded because of
an inconsistent ACTH assay (45 ng/mL) and the adre-
nal mass waso10mm in diameter, 5 cases were excluded
because they had minimal adrenomegaly (or inconclusive
imaging ﬁndings on review, including bilateral ad-
renomegaly) and an ACTH assay was not performed, 6
cases were excluded because a diagnosis of HAC was not
conﬁrmed (although all had adrenal tumors), and 1 case
that received both trilostane and mitotane also had a
partial adrenalectomy and therefore was excluded. In all
cases that were included, the contra-lateral adrenal gland
either was not detected or was o7mm diameter when
examined by ultrasonography. All cases of bilateral
adrenomegaly were excluded (even though it is possible
that some of these dogs may have had bilateral adrenal
tumors).
The diagnosis of HAC was made in 36 of 37 dogs on
the basis of an exaggerated response after an ACTH
stimulation test, failure to suppress cortisol concentra-
tions after a LDDST or both. One case had a reverse
LDDST18 and a compatible UCCR. All 37 cases had a
diagnosis of HAC and an adrenal ultrasound examina-
tion that demonstrated the presence of a unilateral
adrenal mass 410mm. Thirty-one of 37 had an ACTH
concentration o5 ng/mL. In the remaining 6 dogs, the
diagnosis of ADHwas based on histopathology conﬁrm-
ing an adrenal carcinoma (in 2 dogs) or unequivocal
clinical signs, unilateral adrenomegaly (410mm) and re-
sponse to treatment (in 4 dogs).
Thirty-six dogs died before the end of the study. The
one that survived was still alive at the time of manuscript
submission.
Of the 37 dogs included in the study, 13 patients came
from Center 1, 7 patients from Center 2, 5 patients from
Center 3, and 12 patients from Center 4. Although there
was a signiﬁcant difference in the drug treatment regi-
mens preferred by the different centers (P 5 .004), the
diagnostic techniques used to conﬁrm HAC and diag-
nose ADH were the same (Table 1) and there were no
signiﬁcant differences among the age, sex, and breeds of
the dogs (Tables 2 and 3).
There were 37 dogs treated by medical management:
13 with mitotane, 22 with trilostane, and 2 with mitotane
then trilostane. No dogs were treated with mitotane and
trilostane concurrently. The 2 dogs treated with mitotane
and trilostane were excluded from comparisons involving
treatment groups.
There were no signiﬁcant differences among the dogs
in each treatment group when comparing population
measures and clinical ﬁndings (Tables 3 and 4).
There is evidence of a temporal relationship with rela-
tion to drug choice. Although from 1996 to 1998 all dogs
were treated with mitotane (6/6), between 1998 and 2001
both products were available. In this time period, 8 dogs
were treated with trilostane, 6 with mitotane, and 1 with
both drugs. From 2002, 14 dogs were treated with trilo-
stane (because this was the UK veterinary-licensed
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product from 2005), only 1 with mitotane and 1 with
both drugs. If time of treatment is converted into a bi-
nary outcome (before 2002 and 2002 or later), mitotane
was 21 (95% conﬁdence interval [CI] 2.29–192.81) times
more likely than trilostane to be used before the year
2002. When the presence of metastatic disease was ac-
counted for in this analysis, it was not signiﬁcantly
associated with time of treatment or with the choice of
drug treatment.
Median age at diagnosis was 11 years (mean, 11.5;
standard deviation [SD], 1.87; range 7–14 years). Median
weight at diagnosis was 26 kg (mean, 25.5; SD, 13.2;
range 3.2–63 kg). There were 24 female dogs. Of these, 7
were intact and 17 were neutered. There were 13 male
dogs. Of these, 6 were intact and 7 were neutered. There
were 14 breeds represented: 8 Labradors, 2 Labrador
cross breeds, 4 Yorkshire Terriers, 4 Boxers, 2 English
Springer Spaniels, 2 Jack Russell Terriers, 1 each of Pyre-
nean Mountain Dog, Fox Terrier, Scottish Terrier,
Hungarian Vizsla, German Shepherd Dog, Irish Setter,
Rough-Haired Collie, and Border Collie, and 7 cross-
breed dogs.
Two dogs had concurrent disease either at presenta-
tion or within 1 month of diagnosis (1 had a Leydig
tumor and the other had pancreatitis and pyelonephri-
tis). During the course of treatment, 9 more dogs
were recorded as developing concurrent disease. Three
dogs had signs of cardiac disease and were managed
with angiotensin converting enzyme inhibitors and
furosemide, one dog had surgically managed pyometra,
Table 1. Distribution of drug treatment and diagnostic regimen by veterinary center.
Variables Center 1 Center 2 Center 3 Center 4 Total P-Value
Drug treatment regimen
Mitotane 3 (23%) 0 (0%) 0 (0%) 10 (83.3%) 13 (35.1%) .004
Trilostane 9 (69%) 7 (100%) 4 (80%) 2 (16.7%) 22 (59.5%)
Both 1 (8%) 0 (0%) 1 (20%) 0 (0%) 2 (5.4%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Diagnostic regimen
ACTH stimulation test
Performed 13 (100%) 7 (100%) 4 (80%) 12 (100%) 36 (97.3%) .92
Not performed 0 (0%) 0 (0%) 1 (20%) 0 (0%) 1 (2.7%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
LDDST
Not performed 2 (15.4%) 2 (28.6%) 1 (20%) 3 (25%) 8 (21.6%) .96
Performed 11 (84.6%) 5 (71.4%) 4 (80%) 9 (75%) 29 (78.4%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
ACTH
Not performed 0 (0%) 2 (28.6%) 2 (40%) 2 (16.7%) 6 (16.2%) .54
Performed 13 (100%) 5 (71.4%) 3 (60%) 10 (83.3%) 31 (83.8%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
UCCR
Not performed 12 (7.7%) 6 (85.7%) 4 (80%) 12 (100%) 34 (91.9%) .89
Performed 1 (92.3%) 1 (14.3%) 1 (20%) 0 (0%) 3 (8.1%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Pre/post-17OHP
Not performed 13 (100%) 7 (100%) 4 (80%) 10 (83.3%) 34 (91.9%) .84
Performed 0 (0%) 0 (0%) 1 (20%) 2 (16.7%) 3 (8.1%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Abdominal ultrasound
Performed 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) ND
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Thoracic radiography
Not performed 0 (0%) 2 (28.6%) 0 (0%) 0 (0%) 2 (5.41%) .72
Performed 13 (100%) 5 (71.4%) 5 (100%) 12 (100%) 35 (94.59%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Advanced imaging
Not performed 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) ND
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Histopathology
Not performed 10 (76.9%) 6 (85.7%) 5 (100%) 11 (91.7%) 32 (86.5%) .87
Performed 3 (23.1%) 1 (14.3%) 0 (0%) 1 (8.3%) 5 (13.5%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
There was a signiﬁcant difference between choice of drug treatment and center.
ND, not done; P-value not calculated.
ADH, adrenal-dependent hyperadrenocorticism; 17OHP, 17-hydroxyprogesterone; LDDST, low-dose dexamethasone suppression test;
UCCR, urine corticoid creatinine ratio.
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1 dog developed chronic renal failure, 2 dogs had mam-
mary neoplasia, 1 dog developed signs of spinal cord
disease, and 1 dog had neurological signs consistent with
a central nervous system (CNS) space-occupying lesion.
Therefore, 11 of 37 dogs had concurrent disease overall.
Of these dogs, 8 were treated with trilostane, 3 with mi-
totane, and none with both trilostane and mitotane
(Table 4).
Histopathology results were available in 5 dogs. Three
had a postmortem examination and all dogs had unilat-
eral adrenal carcinomas (2 left and 1 right). Two dogs
had antimortem biopsies, which conﬁrmed unilateral ad-
renocortical carcinoma in both. Three of these dogs were
treated with mitotane, 1 with trilostane and 1 with both.
The ﬁnding of adrenal malignancy was not signiﬁcant
between groups (P5 .88), although sample size was very
small.
Of the 36 animals that were dead at date of censor-
ship, 25 were euthanized. In 19 dogs, the cause of
death or reason for euthanasia was recorded; however,
in only some cases were postmortem examinations
performed. Two dogs died of causes that were felt
to be because of the ADH or its treatment. Of these 2
dogs, 1 dog died of metastatic neoplasia and the other
of suspected hypoadrenocorticism (a reported adverse
effect of both mitotane and trilostane treatment). An
additional 8 of the 19 dogs died of causes that were
felt potentially could have been because of ADH or
its treatment. These included signs of collapse, progres-
sive deterioration, poor quality of life, and what was
described as ‘‘old age.’’ An additional 9 of the 19 dogs
died of causes that were thought not be directly
attributable to ADH or its treatment (eg, heart failure,
tracheal collapse, CNS disease, and an infected mam-
mary mass). In the remaining 17 animals, a reason for
death was not recorded. It was felt that the data insufﬁ-
ciently reliable to compare the causes of death between
the treatment groups or with the length of survival.
However, no trends were apparent on visual inspection
of the data.
Table 2. Distribution of the clinical ﬁndings in dogs with ADH by veterinary center.
Variables Center 1 Center 2 Center 3 Center 4 Total P-Values
Invasion of blood vessels
Not detected 13 (100%) 5 (71.4%) 3 (60%) 11 (91.7%) 32 (86.5%) .52
Present 0 (0%) 2 (28.6%) 2 (40%) 1 (8.3%) 5 (13.5%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Concurrent disease (at any point from diagnosis)
Not detected 7 (53.8%) 4 (57.1%) 3 (60%) 12 (100%) 26 (70.3%) .20
Present 6 (46.2%) 3 (42.9%) 2 (40%) 0 (0%) 11 (29.7%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
Presence of metastatic disease
Not detected 11 (84.6%) 4 (57.1%) 4 (80%) 8 (66.6%) 27 (73%) .89
Present 2 (15.4%) 1 (14.3%) 1 (20%) 4 (33.3%) 8 (21.6%)
Missing (ie, not recorded) 0 (0%) 2 (28.6%) 0 (0%) 0 (0%) 2 (5.4%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%)
There were no signiﬁcant intercenter differences between frequencies of blood vessel invasion or presence of concurrent or metastatic dis-
ease.
Table 3. Distribution of population measures by veterinary center and by drug treatment regimen.
Variables Center 1 Center 2 Center 3 Center 4 Total P-Value Mitotane Trilostane Both Total
Fisher’s Exact P-Value
(Mann-Whitney’s
P-Value)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Reproductive status (neutered)
No 7 (53.8%) 1 (14.3%) 3 (60%) 2 (16.7%) 13 (35.14%) .23 3 (23.08%) 10 (45.45%) 0 (0%) 13 (35.14%) .28
Yes 6 (46.2%) 6 (85.7%) 2 (40%) 10 (83.3%) 24 (64.86%) 10 (76.92%) 12 (55.55%) 2 (100%) 24 (64.86%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Gender
Female 7 (53.8%) 5 (71.4%) 3 (60%) 9 (75%) 24 (64.86%) .81 9 (69.23%) 14 (63.64%) 1 (50%) 24 (64.86%) 1
Male 6 (46.2%) 2 (28.6%) 2 (40%) 3 (25%) 13 (35.14%) 4 (30.77%) 8 (36.36%) 1 (50%) 13 (35.14%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Age (years)
11 6 (46.2%) 3 (42.86%) 3 (60%) 6 (50%) 18 (48.65%) .96 7 (53.8%) 11 (50%) 0 (0%) 18 (48.65%) 1 (.76)
411 7 (53.8%) 4 (57.14%) 2 (40%) 6 (50%) 19 (51.35%) 6 (46.2%) 11 (50%) 2 (100%) 19 (51.35%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Weight (kg)
27.4 8 (61.54%) 5 (71.4%) 3 (60%) 5 (41.67%) 21 (56.76%) .72 6 (46.2%) 13 (59.09%) 2 (100%) 21 (56.76%) .5 (.48)
427.4 5 (38.46%) 2 (28.6%) 2 (40%) 7 (58.33%) 16 (43.24%) 7 (53.8%) 9 (40.91%) 0 (0%) 16 (43.24%)
Total 13 (100%) 7 (100%) 5 (100%) 12 (100%) 37 (100%) 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Note that the Fisher’s exact-test excluded the 2 dogs that had both mitotane and trilostane.
There were no signiﬁcant differences in population measures between centers or drug treatment.
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Kaplan-Meier Survival Estimates
The median survival time for all dogs from treatment
was 277 days (95% CI, 102–473 days). Survival times for
dogs in the study population ranged from 4 to 1,341
days. Treatment occurred fairly soon after diagnosis (me-
dian, 11 days; 95% CI, 6–16 days) in all but 1 case. One
dog had an extended time from diagnosis to the start of
treatment (174 days).
All variables were examined for an effect on survival
rates. These statistical tests assumed that the ratio of risk
of death for each group was constant across all strata.22
There was no statistically signiﬁcant difference between
drug treatments. The presence of metastatic disease was
the only variable that had an important and signiﬁcant
effect on survival time.
There was no signiﬁcant difference between survival
times of dogs (n 5 35) treated with either mitotane or
trilostane (P values: log-rank, .15; Wilcoxon, .12; Tar-
one-Ware, .13; and Peto-Peto, .12; Fig 1). However, the
survivorship functions for each treatment crossed over
which implied that the survival outcome for each drug
treatment may have varied over time.22 At the date of
censorship, all dogs treated with mitotane were dead.
The median survival time for dogs on mitotane (n 5 13)
was 102 days (95% CI, 43–277 days). The median sur-
vival time for dogs on trilostane (n 5 22) was 353 days
(95% CI, 95–528 days). The 1-year survival fraction for
dogs on mitotane was 23% (95% CI, 5.6–47.5%),
whereas the 1-year survival fraction for dogs on trilo-
stane was 50% (95% CI, 28.2–68.4%).
All dogs had abdominal ultrasonography and all but 2
also had thoracic radiography for staging. Metastatic
disease was detected in 8 of the 37 dogs and not detected
in 27 dogs. There were 2 dogs for which the presence or
absence of metastatic disease was not recorded, and these
dogs were excluded from further analysis. Dogs without
detected metastatic disease survived longer than those
with metastatic disease (P values: log-rank, o.001;
Wilcoxon, o.001; Tarone-Ware, o.001; and Peto-Peto,
o.001; Fig 2). The median survival time for those dogs
without detected metastatic disease was 402 days (95%
CI, 163–531 days). The median survival time for dogs
with metastatic disease was 61 days (95% CI, 4–172
days). The 1-year survival fraction for dogs without de-
tected metastatic disease was 51.8% (95% CI, 31.9–
Table 4. Distribution of the clinical ﬁndings in dogs with ADH by drug treatment.
Variables Mitotane Trilostane Both Total P-Values
Invasion of blood vessels
Not detected 12 (92.3%) 18 (81.82%) 2 (100%) 32 (86.5%) .83
Present 1 (7.7%) 4 (18.18%) 0 (0%) 5 (13.5%)
Total 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Concurrent disease (at any point from diagnosis)
Not detected 10 (76.9%) 14 (65%) 2 (100%) 26 (70.3%) .45
Present 3 (23.1%) 8 (35%) 0 (0%) 11 (29.7%)
Total 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Presence of metastatic disease
Not detected 9 (69.23%) 17(77.27%) 1 (50%) 27 (72.97%) .37
Present 4 (30.77%) 3 (13.64%) 1 (50%) 8 (21.62%)
Missing (ie, not recorded) 0 (0%) 2 (9.09%) 0 (0%) 2 (5.41%)
Total 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Histopathology
Not performed 10 (76.9%) 21 (95.45%) 1 (50%) 32 (86.5%) .88
Performed 3 (23.1%) 1 (4.55%) 1 (50%) 5 (13.5%)
Total 13 (100%) 22 (100%) 2 (100%) 37 (100%)
Conﬁrmed carcinoma
No 10 (76.9%) 21 (95.45%) 1 (50%) 32 (86.5%) .88
Yes 3 (23.1%) 1 (4.55%) 1 (50%) 5 (13.5%)
Total 13 (100%) 22 (100%) 2 (100%) 37 (100%)
There were no signiﬁcant interdrug differences between frequencies of blood vessel invasion, histopathological examination (conﬁrmation
of a carcinoma), or presence of concurrent or metastatic disease.
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Fig 1. Kaplan-Meier survival curve for both mitotane- and trilo-
stane-treated dogs (n 5 35). Dogs alive at the completion of the
study and those lost to follow-up were censored. The 2 dogs treated
with both mitotane and trilostane were excluded from this analysis.
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68.6%). The 2-year survival fraction was 22.2% (95%
CI, 9.0–39.0%). The 2-month survival fraction for the
dogs with detected metastatic disease was 50% (95% CI,
15.2–77.5%), the 6-month survival fraction was 12.5%
(95% CI, 0.7–42.3%) and 1-year survival fraction was
0%. Of the 8 dogs with detected metastatic disease, 4
were treated with mitotane, 3 with trilostane, and 1 with
both. There was no signiﬁcant difference between the
dogs with and without detected metastases with respect
to drug treatment (P 5 .29). The survival times of the 4
dogs treated with mitotane that had metastatic disease
were 43, 61, 62, and 172 days. The survival times of the 3
dogs that were treated with trilostane were 4, 50, and 292
days. The 1 dog with metastatic disease, which was
treated with both drugs, survived 159 days. No statisti-
cal analysis was attempted on these data.
The 1-year survival fraction for dogs with metastatic
disease was 0% regardless of the drug treatment regimen.
In dogs with metastatic disease treated with mitotane, the
median survival time was 61 days (lower 95% CI, 43
days; upper 95% CI, not calculated) and for trilostane
also was 61 days (95% CI, 4–172 days). The 1-year sur-
vival fraction for dogs without metastatic disease was
33.3% (95% CI, 7.8–62.3%) if they were treated with
mitotane and 50.0% (95% CI, 29.9–67.2%) if treated
with trilostane. Both drug treatments had lower survival
fractions at 2 years (mitotane, 22.2%; 95% CI, 3.4–
51.3% and trilostane, 23.1%; 95% CI, 9.4–40.3%). In
dogs without metastatic disease treated with mitotane,
the median survival time was 195 days (95% CI, 33–952
days) and for trilostane was 353 days (95% CI, 163–531
days).
Cox Proportional Hazards Model. In the ﬁnal multi-
variable Cox proportional hazards model the presence of
metastatic disease (HR 5.3; 95%CI, 2.06–13.5; P5 .001)
was signiﬁcantly associated with an increased hazard of
death. There were no other predictor variables that were
signiﬁcant at either the level of the univariable or multi-
variable model. Speciﬁcally, there was no signiﬁcant
effect of drug treatment (mitotane compared with trilo-
stane or both drug treatments) on survival rates. This
remained true when the dogs treated with both mitotane
and trilostane (n 5 2) were subsequently excluded from
the analyses. The lack of a signiﬁcant ﬁnding for drug
treatment was likely because of the small number of ob-
servations in this study (total n 5 37) and thus a lack of
power to detect small effects (HRo 5).
The confounding effects of drug treatment and
veterinary center were assessed in the ﬁnal model.
Neither variable was signiﬁcant or had an important
effect on the HRs associated with the presence of
metastatic disease. Interaction terms were explored, but
were not included in the ﬁnal model because of the
small number of observations in the study. The ﬁnal
model did not violate the proportional hazards assump-
tion (based on Schoenﬁeld’s residuals). The model
was checked for outliers and inﬂuential points. Two
dogs were identiﬁed as inﬂuential and the model was re-
run without these observations. However, omission of
these observations had no signiﬁcant effect on the ﬁnal
model.
Discussion
This study evaluated factors that may inﬂuence sur-
vival in dogs treated for ADH with either mitotane or
trilostane. There was a signiﬁcant difference in survival
between animals with metastatic disease at the time of
diagnosis and those without, but no signiﬁcant difference
in survival between dogs treated with mitotane or trilo-
stane. The fact that the study was able to detect a
signiﬁcant difference between dogs with and without
metastatic disease demonstrates that the study was sufﬁ-
ciently well powered to detect large differences.
Therefore if there were, in fact, a difference between mi-
totane and trilostane, then it was a small effect, which
this study could not detect. This study provides impor-
tant information for clinicians who are presented with
dogs with ADH, because, until now, there may have been
a presumption that by an adrenocorticolytic treatment
(such as mitotane) would be superior. The results of the
present study do not support this view.
Complete removal of a functional adrenal tumor caus-
ing HAC offers a good prognosis if dogs survive the
immediate postoperative period. In 1 study, the median
survival time after surgical removal was just o2 years,
although some dogs survived for 44 years.23 However,
animals with untreated ADH are difﬁcult surgical candi-
dates because of the increased anesthetic risk (because of
poor respiratory and hepatic function), hypercoagulabil-
ity (leading to an increased risk of pulmonary
thromboembolism), poor vascular tone (leading to poor
hemostasis), delayed primary wound healing, and
difﬁculty in surgical exposure. Acute postoperative hy-
poadrenocorticism because of pre-existing contra-
lateral adrenal atrophy and postoperative pancreatitis
and peritonitis, as well as ischemic necrosis and multiple
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Fig 2. Kaplan-Meier survival curve for dogs (n 5 35) with and
without metastatic disease. Dogs alive at the completion of the
study and those lost to follow-up were censored. There were 2 dogs
for which the presence or absence of metastatic disease was not re-
ported and these dogs were excluded.
257Medical Management of ADH
organ failure, are described.23–26 Postoperative intensive
care facilities therefore are essential. Even in referral
centers, perioperative mortality rates are in the range of
19–60%.23–26 The costs of surgical management may be
considerable in the short term. For all of these reasons,
surgery can be considered a ‘‘high gain but high risk’’
strategy and therefore many owners opt for medical
treatment rather than surgical intervention.
In our study population, it is presumed that the dogs
had factors that prevented surgery as a viable option,
such as gross metastases at the time of diagnosis, local
invasiveness, and ﬁnancial or owner issues. Because of
the retrospective nature of this study, it was unclear in
some cases why medical management was selected, and
there could be concern that surgery was precluded be-
cause of advanced disease. However, because very few
animals in the study had evidence of metastases or blood
vessel invasion, concern about advanced disease was not
an important factor.
Having decided to treat a case medically, the criteria
used by clinicians to select a particular drug treatment
were not clear because of the retrospective nature of this
study. The choice of drug treatment may have been in-
ﬂuenced by practical factors such as cost, availability (a
Special Treatment Authorization is required to obtain
mitotane in the United Kingdom), and individual clini-
cian or center preference. The last two of these likely were
major factors in the selection criteria. In the early study
period, trilostane was not readily available in the United
Kingdom, and therefore from the years 1996–1998 all
dogs were treated with mitotane. Between 1998 and 2001
both products were available. From 2002 onward, 14/16
dogs were treated with trilostane (as this was the UK
veterinary-licensed product from 2005). It is therefore
likely that clinician choice was inﬂuenced by drug avail-
ability. It is known that dogs in both the mitotane and
trilostane groups were from the same general population
of dogs affected with ADH as evidenced by the lack of
signiﬁcant differences between any of the population
variables measured (Table 4). Crucially, there were no
detectable differences in the numbers of dogs with signs
of overt malignancy (blood vessel invasion or presence of
metastatic disease) that were prescribed either mitotane
or trilostane.
Two protocols for the treatment of PDH with mitotane
are described,12 one utilizes selective adrenocorticolysis
and includes an induction period of daily doses of mito-
tane followed by a weekly maintenance dose (as in this
study),2 the second is a high-dose nonselective protocol de-
signed to completely destroy the adrenal cortices, followed
by daily and lifelong corticosteroid and mineralocorticoid
supplementation.26,27 There have been no studies examin-
ing the use of a nonselective protocol in the treatment of
ADH. In PDH, the selective destruction of the adrenal
cortices with mitotane is considered to be safer for the pa-
tient, because the zona glomerulosa and mineralocorticoid
production are preserved. Therefore a ‘‘selective pro-
tocol’’ was chosen for the ADH cases in this study because
it decreased the risks of adverse effects (including hypo-
adrenocorticism) and because this protocol is the only one
that has been reported in ADH cases.12,27
Most dogs described here received the current recom-
mended trilostane dosage for PDH of 2.2–6.7mg/kg
from the manufacturer’s data sheet. Two small breed
dogs in this study (weights, 3.2 and 5 kg) received trilo-
stane but at a time when the 30mg capsule was the
smallest formulation available, hence their doses were
9.3 and 6mg/kg, respectively. However, at the time of
presentation, the recommended trilostane dosage was
higher than is currently used and hence these dogs still
fell within manufacturer guidelines of 2–12mg/kg.
Although some authors suggest that mitotane dosage
should be increased when treating dogs with ADH,28
this study does not support increased trilostane dosage
over that used to manage PDH, but work in this area is
ongoing.
A change in trilostane treatment usage has occurred
over the study period. Current literature reﬂects the fact
that performing ACTH stimulation tests for monitoring
response to treatment (ie, at 4–6 hours postmedication),
starting dosage, and therapeutic targets for trilostane still
are under review for patients with ADH.10
This study was possible because for a period of time
UK centers were using both trilostane and mitotane
for medical management of HAC. The retrospective
study design was chosen to encompass the period of
time when both trilostane and mitotane were available
as medical treatment for HAC. Because of the cascade
system of veterinary prescribing in Europe, trilostane
now is the authorized product and therefore is consid-
ered to be the ﬁrst choice for the treatment of PDH. A
prospective study would therefore be difﬁcult to com-
plete. In addition, because the treatment protocols are so
different, it would be difﬁcult to design a blinded trial.
Furthermore, a multicenter approach over a number of
years was deemed necessary because of the rarity of this
disease. However, with this design there is always a risk
that selection bias may be introduced as a result of differ-
ences among study populations from different veterinary
centers. In this study, there was variation among centers
regarding the choice of drug treatment. However, as
there was no geographical variation found when age at
diagnosis, weight at diagnosis, and reproductive status
were compared, it was concluded that the dogs from each
center were derived from populations that were not sub-
stantially different and could therefore be combined
for further analysis. Comparisons among centers
and treatment groups in terms of breed were not possi-
ble because of the small numbers of animals in some of
the breed categories.
Because there are no published reports describing
survival of dogs with HAC that did not undergo any
form of treatment, it is impossible to compare with his-
torical ‘‘no treatment’’ controls. In addition, direct
comparison of survival times from this study with histor-
ical groups of surgically managed dogs is not
recommended because it cannot be guaranteed that the
dogs are from the same population, meaning selection
bias may be introduced. Prospective randomized studies
comparing surgery to medical management may be difﬁ-
cult given the ﬁnancial differences and difference in
short-term risk.
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One limitation of this study (and of other similar studies)
is that the histological subtype of the adrenal tumor was
not established in most cases. Percutaneous antemortem
adrenal biopsies are a high-risk procedure and as such are
not routinely obtained. The histological tumor type is
likely to have a substantial effect on survival.29 Given that
approximately half of dogs with ADH will have a malig-
nant adrenal tumor,13 it is likely that a proportion of the
dogs in this study had malignant neoplasia. If this is true,
then there may have been an adverse affect on survival.
However, because of the retrospective nature of this study,
it was not possible to evaluate this variable.
Another potential limitation of this study was that the
date of institution of medical treatment was taken as the
start date for survival analysis because it is a clearly de-
ﬁned point in time. Only 1 dog in the current study had a
prolonged period of time between diagnosis and treat-
ment (174 days). This dog had pancreatitis and
pyelonephritis at the time of diagnosis of ADH (con-
ﬁrmed by LDDST, ACTH concentration ofo5.0 ng/mL,
and a large unilateral adrenal mass on abdominal ultra-
sonography) and therefore was medically managed for
these conditions before initiating mitotane treatment.
Despite this, if the date of diagnosis of all patients is used
for analysis, the same pattern of signiﬁcance is seen in all
variables evaluated in this study.
Dogs in this study tended to be middle- to older-aged
and of medium to large body size, which is in agreement
with previous studies.13,30 Forty-six percent of dogs in
the study were420 kg.30 Similar to other investigations,
one-third of the dogs in this study were Labrador Re-
trievers or Labrador Retriever cross breeds.30 However,
it is unclear if this represents a true increased prevalence
in this breed or is related to breed popularity bias within
the United Kingdom.
Almost one-third of dogs (11/37) in this study had
concurrent disease during follow-up, and it is likely in
some cases that concurrent disease had an impact on sur-
vival. In 9 dogs, death or the decision to perform
euthanasia was thought to be because of signs of another
disease unlikely related to the ADH (eg, spinal disease,
cardiac disease, mammary neoplasia). A previously pub-
lished study found that the majority of animals with
PDH did not die because of diseases associated with
PDH or its treatment but rather failure of other organs
(eg, heart, liver, kidneys), unrelated neoplasia, or geriat-
ric diseases (eg, gradual deterioration, incontinence).2
The frequency of concurrent disease could be viewed as
a limitation of this study, but because of the study pop-
ulation (median age, 11 years) some form of concurrent
disease in a proportion of the dogs is to be expected. In
addition, the quality of life of the animals or the efﬁcacies
of the treatments were not assessed in this retrospective
study in either treatment group.
The number of dogs enrolled in this study is compara-
ble to similar studies on ADH in the veterinary
literature.13,23–25,29 This study includes the use of trilo-
stane treatment in 22 dogs with ADH and is therefore the
largest case series of its kind currently published. Despite
this, the study was underpowered to detect small effects.
The small study size likely reﬂects the rarity of adrenal-
dependent as opposed to pituitary-dependent disease. As
such, future studies will require further collaborations
among large numbers of veterinary centers to ensure en-
rollment of sufﬁcient numbers of ADH dogs to detect
small differences.
In conclusion, medical management is a reasonable
treatment option for ADH dogs. It is unlikely that the
choice of treatment (mitotane or trilostane) has a major
effect on survival times in dogs medically managed for
ADH. The presence of metastatic disease adversely
affects outcome. Additional large clinical studies are re-
quired to support these ﬁndings and allow for clear
treatment recommendations.
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